There have been suggestions of institutional racism in UK mental health services.
Potential confounding factors (23 in total) were predetermined and details were obtained from case notes, self-report, or by measurement or calculation and confirmed by nursing or medical staff where appropriate. Clinical Global Impression-Severity 10 (CGI-S) was rated on the day of data collection (nurse or medical staff assessment).
A sample size of 298 was calculated to be required to give an 80% chance of detecting a 5% absolute difference for our main outcome (dose) (a=0.05, r=0.8). We aimed to compare four outcomes (dose, rate of polypharmacy, high-dose prescribing and use of atypical antipsychotics) between our two groups and to adjust comparisons for the effect of confounding (predictive) variables. For the outcome of dose we used a linear regression model to provide an estimate of unadjusted effect of ethnicity on dose. Potential confounding variables were then tested to identify predictive factors (significance level of P50.1). Predictive factors were then included in a rerun regression model, producing adjusted effect size for ethnicity. Transformations were used when necessary. A similar approach was used for the binary outcomes of high dose, polypharmacy and prescribing of atypical drugs, but with logistic regression modelling used.
Results
We approached 300 patients and 255 gave informal informed consent to be interviewed. Of the 45 patients who declined to take part, 21 (46.7%) were Black, 23 (51.1%) were male and the mean age was 41.7 years. Details of included patients are given in the online Table DS1 .
Median dose was 58.3% for White patients and 50.0% for Black patients (adjusted effect size=0.14, 95% CI -0.34 to 0.63; P=0.56). High-dose antipsychotics (4100% licensed maximum) were prescribed to 15.1% of White and 11.7% of Black patients (adjusted OR=0.5, 95% CI 0.19-1.33; P=0.16) and polypharmacy to 25.7% and 31.1% respectively (adjusted OR=3.05, 95% CI 1.44-6.46; P=0.004). With polypharmacy, the adjusted odds ratio was largely driven by centre differences: one centre showed an exceptionally high rate of polypharmacy in Black patients (74% v. 37% in White patients; other centres: 13% v. 17% and 16% v. 10% respectively). There was no difference in the prescribing of atypical antipsychotics (White 77.6%, Black 68.9%: adjusted OR=0.57, 95% CI 0.21-1.5; P=0.25).
Discussion
In this study, ethnicity was not significantly associated with dose of antipsychotic, the prescribing of high-dose antipsychotics or the use of atypical antipsychotics. Prescribing quality was thus no worse for Black patients than for White patients. Only the outcome of adjusted odds ratio for antipsychotic polypharmacy showed any association with ethnicity. This is an important observation but it should be noted that absolute rates of polypharmacy differed markedly in only one centre and the overall difference in prevalence was small (25.7% for White v. 31.1% for Black patients).
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Ethnicity and quality of antipsychotic prescribing among in-patients in south London Our findings are therefore in some contrast to studies which suggest a higher likelihood of higher-dose prescribing in Black patients [2] [3] [4] [5] and a lower use of atypical drugs. 5 This may reflect true differences in practice at different times (there is evidence of ethnic differences in prescribing in the 1990s in south London) 11 or in different locations (many of the studies [3] [4] [5] examine US prescribing) but may also be linked to the relatively limited extent of adjustment for confounding variables in previous studies. Adjustment for these confounders is essential to the process of establishing or otherwise ethnicity as having an association with prescribing quality.
There were several limitations in our study design. We did not meet our recruitment target of 298 patients, although confidence intervals ultimately excluded major differences in outcome, particularly with respect to a possibility of a lower quality of prescribing for Black people. In addition, some of our data collection relied on patient self-report -a notoriously unreliable source, especially, perhaps, in psychiatric in-patients. Also, our assessment of clinic status was approximate (using the CGI-S scale) and may not of have been relevant to patients' condition at the time of the initial prescription. Lastly, our sample was exclusively in-patients and so our results may not generalise to the majority of patients now treated in the community.
Notwithstanding these limitations, it is reasonable to conclude that in this study prescribing quality did not differ substantially between Black and White patients. Black patients were not prescribed higher doses than White patients. Black patients are more likely to receive antipsychotic polypharmacy, but this difference was only noticeably higher in one centre. Black patients were just as likely as White patients to receive atypical antipsychotics. 
